Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at Guggenheim

Maze Therapeutics (NASDAQ:MAZE) had its price objective boosted by Guggenheim from $46.00 to $58.00 in a research note released on Wednesday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other equities analysts have also recently issued reports on MAZE. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Wells Fargo & Company started coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target for the company. Wedbush lifted their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, BTIG Research boosted their target price on Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a research note on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.57.

Maze Therapeutics Stock Performance

NASDAQ:MAZE opened at $46.48 on Wednesday. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $49.25. The firm has a market cap of $2.24 billion, a PE ratio of -2.22 and a beta of 4.47. The business has a 50 day moving average price of $43.79 and a 200-day moving average price of $34.04.

Insiders Place Their Bets

In related news, SVP Amy Bachrodt sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.58, for a total value of $405,800.00. Following the sale, the senior vice president owned 12,965 shares in the company, valued at approximately $526,119.70. This trade represents a 43.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the sale, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 200,000 shares of company stock valued at $8,254,792.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics during the fourth quarter valued at $145,000. Invesco Ltd. grew its stake in shares of Maze Therapeutics by 1.5% during the 4th quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock valued at $5,553,000 after purchasing an additional 1,971 shares during the period. ADAR1 Capital Management LLC increased its position in shares of Maze Therapeutics by 589.3% during the 4th quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock valued at $7,438,000 after purchasing an additional 153,487 shares during the last quarter. XTX Topco Ltd increased its position in shares of Maze Therapeutics by 22.9% during the 4th quarter. XTX Topco Ltd now owns 33,021 shares of the company’s stock valued at $1,368,000 after purchasing an additional 6,154 shares during the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of Maze Therapeutics in the 4th quarter worth approximately $2,536,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.